APN-401 is under clinical development by InvIOs and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect APN-401’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 11 Mar 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their APN-401 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
APN-401 is under development for the treatment of various solid tumors. It is an autologous cell therapy. The drug candidate is administered through intravenous route and acts by targeting the E3 ubiquitin ligase Cbl-b.
It was under development for the treatment of melanoma, renal carcinoma (kidney), metastatic pancreatic cancer, metastatic colorectal cancer.
Quick View APN-401 LOA Data
|Highest Development Stage|